Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Assets (2016 - 2025)

Historic Assets for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $808.1 million.

  • Ocular Therapeutix's Assets rose 7645.67% to $808.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $808.1 million, marking a year-over-year increase of 7645.67%. This contributed to the annual value of $808.1 million for FY2025, which is 7645.67% up from last year.
  • As of Q4 2025, Ocular Therapeutix's Assets stood at $808.1 million, which was up 7645.67% from $410.9 million recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Assets registered a high of $808.1 million during Q4 2025, and its lowest value of $122.6 million during Q2 2023.
  • Moreover, its 5-year median value for Assets was $236.9 million (2021), whereas its average is $315.6 million.
  • In the last 5 years, Ocular Therapeutix's Assets plummeted by 3147.23% in 2023 and then skyrocketed by 32191.53% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Assets (Quarter) stood at $204.9 million in 2021, then decreased by 27.14% to $149.3 million in 2022, then soared by 68.84% to $252.1 million in 2023, then soared by 81.68% to $457.9 million in 2024, then soared by 76.46% to $808.1 million in 2025.
  • Its Assets stands at $808.1 million for Q4 2025, versus $410.9 million for Q3 2025 and $451.3 million for Q2 2025.